China Nuclear Energy Technology Corporation Limited (HKG:0611)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.4850
0.00 (0.00%)
Aug 1, 2025, 4:08 PM HKT

Inozyme Pharma Ratios and Metrics

Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
8986485199451,142867
Upgrade
Market Cap Growth
25.00%25.00%-45.10%-17.32%31.82%120.00%
Upgrade
Enterprise Value
7,8677,1264,6094,8174,2213,755
Upgrade
Last Close Price
0.480.350.280.510.870.66
Upgrade
PE Ratio
7.405.344.7710.2412.7215.19
Upgrade
PS Ratio
0.650.470.300.440.440.41
Upgrade
PB Ratio
0.490.360.290.560.890.77
Upgrade
P/TBV Ratio
0.500.360.300.570.930.78
Upgrade
P/FCF Ratio
----4.66-
Upgrade
P/OCF Ratio
1.421.021.8119.383.952.25
Upgrade
EV/Sales Ratio
5.715.172.682.251.631.78
Upgrade
EV/EBITDA Ratio
10.419.868.7011.2411.3019.14
Upgrade
EV/EBIT Ratio
20.2818.4014.3419.1219.0734.70
Upgrade
EV/FCF Ratio
-7.43---17.22-
Upgrade
Debt / Equity Ratio
4.314.314.393.082.843.11
Upgrade
Debt / EBITDA Ratio
10.4010.4014.0911.709.3917.06
Upgrade
Debt / FCF Ratio
----14.78-
Upgrade
Asset Turnover
0.130.130.170.250.340.33
Upgrade
Inventory Turnover
-----20.42
Upgrade
Quick Ratio
0.870.870.990.690.910.81
Upgrade
Current Ratio
1.021.021.211.151.131.01
Upgrade
Return on Equity (ROE)
7.23%7.23%6.75%6.62%7.89%8.60%
Upgrade
Return on Assets (ROA)
2.20%2.20%1.93%1.81%1.81%1.04%
Upgrade
Return on Capital (ROIC)
2.56%2.56%2.44%2.67%2.90%1.66%
Upgrade
Return on Capital Employed (ROCE)
5.20%5.20%4.30%5.90%6.80%3.60%
Upgrade
Earnings Yield
13.52%18.74%20.97%9.77%7.86%6.58%
Upgrade
FCF Yield
-117.93%-163.42%-358.98%-77.52%21.46%-80.25%
Upgrade
Buyback Yield / Dilution
---11.46%-26.54%--
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.